Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

BioNTech SE (BNTX)

Compare
94.95
-0.45
(-0.47%)
At close: March 28 at 4:00:02 PM EDT
94.00
-0.95
(-1.00%)
After hours: March 28 at 7:37:15 PM EDT
Loading Chart for BNTX
  • Previous Close 95.40
  • Open 95.84
  • Bid 94.71 x 200
  • Ask 120.79 x 100
  • Day's Range 93.72 - 96.01
  • 52 Week Range 76.53 - 131.49
  • Volume 616,895
  • Avg. Volume 782,647
  • Market Cap (intraday) 22.785B
  • Beta (5Y Monthly) 0.31
  • PE Ratio (TTM) --
  • EPS (TTM) -2.97
  • Earnings Date May 5, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 2, 2022
  • 1y Target Est 138.06

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vaccine ecosystem. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

www.biontech.de

6,772

Full Time Employees

December 31

Fiscal Year Ends

Recent News: BNTX

View More

Performance Overview: BNTX

Trailing total returns as of 3/29/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .

YTD Return

BNTX
15.66%
MSCI WORLD (^990100-USD-STRD)
1.97%

1-Year Return

BNTX
2.93%
MSCI WORLD (^990100-USD-STRD)
5.76%

3-Year Return

BNTX
42.17%
MSCI WORLD (^990100-USD-STRD)
16.84%

5-Year Return

BNTX
74.92%
MSCI WORLD (^990100-USD-STRD)
0.00%

Compare To: BNTX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BNTX

View More

Valuation Measures

As of 3/28/2025
  • Market Cap

    22.79B

  • Enterprise Value

    4.93B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    7.72

  • Price/Book (mrq)

    1.09

  • Enterprise Value/Revenue

    1.66

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -24.18%

  • Return on Assets (ttm)

    -3.53%

  • Return on Equity (ttm)

    -3.36%

  • Revenue (ttm)

    2.75B

  • Net Income Avi to Common (ttm)

    -665.3M

  • Diluted EPS (ttm)

    -2.97

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.78B

  • Total Debt/Equity (mrq)

    1.31%

  • Levered Free Cash Flow (ttm)

    534.99M

Research Analysis: BNTX

View More

People Also Watch